Spring Bank Pharmaceuticals Reports Second Quarter 2019 Financial and Operational Results and Provides Business Development Update

NEXT STORY
Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results
PREV STORY
Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Biopharmaceutical Excipients Market Size Will Reach USD 3.07 Billion by 2026: Facts & Factors

author_avatar
NASDAQ Market News

CARP to host National Preventive Health and Aging Education Event

author_avatar
NASDAQ Market News

VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer

author_avatar
NASDAQ Market News